Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.75 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.74 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.74 |
| ▸ | SCN1A | P35498 | 3/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.74 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.74 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.74 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | THRB | P10828 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3675730 | 0.93 | CYP3A4 (0.78) | CYP3A4LMNAKDM4ECYP2D6ALDH1A1 | |
| SCHEMBL13841519 | 0.93 | CYP3A4 (0.78) | CYP3A4LMNAKDM4ECYP2D6ALDH1A1 | |
| SCHEMBL3677893 | 0.92 | KDM4E (0.77) | CYP3A4LMNAKDM4ECYP2D6ALDH1A1 | |
| SCHEMBL3683666 | 0.90 | CYP3A4 (0.75) | CYP3A4LMNAKDM4ECYP2D6ALDH1A1 | |
| SCHEMBL3678059 | 0.90 | KDM4E (0.74) | CYP3A4LMNAKDM4ECYP2D6ALDH1A1 | |
| SCHEMBL3680691 | 0.90 | KDM4E (0.82) | CYP3A4LMNAKDM4ECYP2D6ALDH1A1 | |
| SCHEMBL3673224 | 0.90 | KDM4E (0.82) | CYP3A4LMNAKDM4ECYP2D6ALDH1A1 | |
| SCHEMBL10102106 | 0.90 | KDM4E (0.82) | CYP3A4LMNAKDM4ECYP2D6ALDH1A1 | |
| SCHEMBL6549252 | 0.90 | KDM4E (0.82) | CYP3A4LMNAKDM4ECYP2D6ALDH1A1 | |
| SCHEMBL10102474 | 0.90 | KDM4E (0.82) | CYP3A4LMNAKDM4ECYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649094-B2 | Optically active compounds, method for kinetic optical resolution of carboxylic acid derivatives and catalysts therefor | DAISO CO., LTD. (JP) | 2010-01-19 | — | — | US | disclosed |
| EP-1477488-B1 | NOVEL OPTICALLY ACTIVE COMPOUNDS, METHOD FOR KINETIC OPTICAL RESOLUTION OF CARBOXYLIC ACID DERIVATIVES AND CATALYSTS THEREFOR | DAISO CO LTD (JP) | 2009-08-26 | — | — | EP | disclosed |
| US-20050154209-A1 | Novel optically active compounds, method for kinetic optical resolution of carboxylic acid derivatives and catalysts therefor | OSAKA SODA CO., LTD. (JP) | 2005-07-14 | — | — | US | disclosed |
| EP-1477488-A1 | NOVEL OPTICALLY ACTIVE COMPOUNDS, METHOD FOR KINETIC OPTICAL RESOLUTION OF CARBOXYLIC ACID DERIVATIVES AND CATALYSTS THEREFOR | DAISO CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154209-A1 | Novel optically active compounds, method for kinetic optical resolution of carboxylic acid derivatives and catalysts therefor | FAR1, TECR, FFAR1 | CYP3A4 93/4885LMNA 1880/4885KDM4E 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.